Inactive Instrument

News VentriPoint Diagnostics Ltd. Toronto S.E.

Equities

VPT

CA92281P2008

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect	06-24	AQ
Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director	06-13	CI
Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management	06-13	AQ
Ventripoint Diagnostics Announces Shareholder Update and Teleconference	06-11	AQ
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration	05-06	CI
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration	05-06	AQ
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology	05-01	CI
Duke University Health Center -- One of America's Top Heart-care Institutions and Innovators -- Purchases Ventripoint's AI Heart-scan Technology	05-01	AQ
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding	04-10	CI
Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call	03-28	AQ
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2)	03-04	CI
Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use	03-04	AQ
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences	02-20	CI
Ventripoint Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences	02-20	AQ
Ventripoint Announces Changes to The Board of Directors	02-13	AQ
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO	02-05	CI
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President	02-05	CI
Ventripoint Begins 2024 with Leadership Change	02-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VentriPoint Diagnostics Ltd. Toronto S.E.

Equities

VPT

CA92281P2008

Summary

Filters